The Bowel CLEAnsing: A National Initiative (B-CLEAN)

September 12, 2018 updated by: Alan Barkun
The purpose of this study is to compare diet, type of bowel preparation and time of colonoscopy to determine if one method is better than the other and, if they are the same, identify the one which is the most convenient for the patients.

Study Overview

Detailed Description

The objective of the current proposed trial is thus to compare the cleanliness achieved with PEG high-volume (2L+2L) split-dose versus PEG (1L+1L)+Bisacodyl low-volume split-dose, or PEG high volume (4L) non-split day before versus PEG low volume (2L) non-split same day preparation, according to time of endoscopy (early or later), as well as assess the role of diet (low residue or clear liquid diet) according to these different Canadian outpatient preparation regimens.

Study Type

Interventional

Enrollment (Actual)

3476

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Québec, Canada, G1S 4L8
        • Hôpital St-Sacrement, CHU de Québec-Université Laval
    • Alberta
      • Calgary, Alberta, Canada, T2N 4Z6
        • Forzani & MacPhail Colon Cancer Screening Centre
      • Edmonton, Alberta, Canada, T6G 2X8
        • University of Alberta Hospital
    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 2K5
        • St. Paul's Hospital
    • Manitoba
      • Winnipeg, Manitoba, Canada, R2H 2A6
        • Health Sciences center and St. Boniface Hospital
    • Nova Scotia
      • Halifax, Nova Scotia, Canada, B3H 2Y9
        • QEII HSC
    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Western University
      • Ottawa, Ontario, Canada, K1H 1A2
        • The Ottawa Hospital
    • Quebec
      • Montreal, Quebec, Canada, H2W 2J3
        • CHUM
      • Montreal, Quebec, Canada, H3G 1A4
        • McGill University Health Centre

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Outpatients
  • 18 years or older
  • Able to comprehend the trial
  • Have an indication for full colonoscopy

Exclusion Criteria:

Subjects are excluded from enrollment into the study if any of the following are present:

General exclusion criteria:

  • Subject refusal
  • Previous bowel preparation in the last 14 days
  • Pregnancy or breastfeeding
  • Reduced mobility

Medical/Endoscopic exclusion criteria:

  • Suspected or diagnosed with bowel obstruction
  • Any colonic surgery
  • Toxic megacolon
  • Ileus
  • Ischemic colitis
  • Decompensated heart failure
  • Severe acute renal failure
  • Severe liver disease
  • Severe electrolyte imbalance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 1) Early colonoscopy; 2) High-dose, split-dose; 3)Clear liquid
Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
Other Names:
  • Colyte® or PegLyte®
"Early" appointments: 7:30 AM to 10h30 AM
Active Comparator: 1) Early colonoscopy; 2) High-dose, split-dose; 3)Low residue
Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
Other Names:
  • Colyte® or PegLyte®
"Early" appointments: 7:30 AM to 10h30 AM
Active Comparator: 1) Early colonoscopy; 2) Low volume split-dose; 3)Clear liquid
"Early" appointments: 7:30 AM to 10h30 AM
Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
Other Names:
  • Bi-PegLyte®
Active Comparator: 1) Early colonoscopy; 2) Low volume split-dose; 3)Low residue
"Early" appointments: 7:30 AM to 10h30 AM
Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
Other Names:
  • Bi-PegLyte®
Active Comparator: 1) Early colonoscopy; 2) High-dose, day before; 3)Clear liquid
"Early" appointments: 7:30 AM to 10h30 AM
Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
Other Names:
  • Colyte® or PegLyte®
Active Comparator: 1) Early colonoscopy; 2) High-dose, day before; 3)Low residue
"Early" appointments: 7:30 AM to 10h30 AM
Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
Other Names:
  • Colyte® or PegLyte®
Active Comparator: 1) Later colonoscopy; 2) High-dose, split-dose; 3)Clear liquid
Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
Other Names:
  • Colyte® or PegLyte®
"Later" appointments: 10:30 AM to 4:30 PM.
Active Comparator: 1) Later colonoscopy; 2) High-dose, split-dose; 3)Low residue
Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
Other Names:
  • Colyte® or PegLyte®
"Later" appointments: 10:30 AM to 4:30 PM.
Active Comparator: 1) Later colonoscopy; 2) Low volume split-dose; 3)Clear liquid
Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
Other Names:
  • Bi-PegLyte®
"Later" appointments: 10:30 AM to 4:30 PM.
Active Comparator: 1) Later colonoscopy; 2) Low volume split-dose; 3)Low residue
Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
Other Names:
  • Bi-PegLyte®
"Later" appointments: 10:30 AM to 4:30 PM.
Active Comparator: 1) Later colonoscopy; 2) Low volume day before; 3)Clear liquid
"Later" appointments: 10:30 AM to 4:30 PM.
Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
Other Names:
  • Bi-PegLyte®
Active Comparator: 1) Later colonoscopy; 2) Low volume day before; 3)Low residue
"Later" appointments: 10:30 AM to 4:30 PM.
Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
Other Names:
  • Bi-PegLyte®

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Bowel cleansing according to the Boston Scale
Time Frame: Day of colonoscopy
Day of colonoscopy

Secondary Outcome Measures

Outcome Measure
Time Frame
Subject willingness to repeat the preparation (survey)
Time Frame: Day of colonoscopy
Day of colonoscopy
Withdrawal time and total procedural time
Time Frame: Day of colonoscopy
Day of colonoscopy
Cecal or ileal intubation rate for colonoscopies
Time Frame: Day of colonoscopy
Day of colonoscopy
Polyp detection and polypectomy rate
Time Frame: Day of colonoscopy
Day of colonoscopy
Right colon polyp detection rate
Time Frame: Day of colonoscopy
Day of colonoscopy
Specific lesional rates identified according to pathology
Time Frame: up to 30 days
up to 30 days
% of preparation taken by the subject
Time Frame: Day of colonoscopy
Day of colonoscopy
Subject travel time to endoscopy unit (hrs)
Time Frame: Day of colonoscopy
Day of colonoscopy
Incontinence
Time Frame: Day of colonoscopy
Day of colonoscopy
Fecal Immunochemical Test value
Time Frame: Day of colonoscopy
Day of colonoscopy
Montreal score compared to BBPS
Time Frame: Day of colonoscopy
Day of colonoscopy
Ottawa Bowel Preparation Scores compared to BBPS
Time Frame: Day of colonoscopy
Day of colonoscopy

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2016

Primary Completion (Actual)

September 1, 2018

Study Completion (Actual)

September 1, 2018

Study Registration Dates

First Submitted

September 1, 2015

First Submitted That Met QC Criteria

September 9, 2015

First Posted (Estimate)

September 11, 2015

Study Record Updates

Last Update Posted (Actual)

September 13, 2018

Last Update Submitted That Met QC Criteria

September 12, 2018

Last Verified

September 1, 2018

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • V2015-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Subjets Requiring a Colonoscopy

Clinical Trials on High volume PEG split-dose

Subscribe